Sionna Therapeutics (NASDAQ:SION) Downgraded to "Neutral" Rating by BTIG Research

Key Points

• BTIG Research downgraded Sionna Therapeutics to “neutral” from “buy,” joining several analysts who have recently lowered ratings. The stock has an overall “hold” consensus and an average price target of $42.22.
• Sionna shares plunged $46.38 to $4.67 in Monday trading on exceptionally heavy volume, near the company’s 52-week low. The selloff followed disappointing clinical results, including the discontinuation of the SION-719 cystic fibrosis program.
• The company also reported a quarterly loss of $0.66 per share, missing the $0.64 consensus estimate, while insiders sold 403,726 shares worth approximately $18.3 million over the past 90 days.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) was downgraded by BTIG Research from a "buy" rating to a "neutral" rating in a research note issued on Monday.

Several other equities research analysts also recently weighed in on the company. Guggenheim reissued a "neutral" rating on shares of Sionna Therapeutics in a report on Monday. Stifel Nicolaus reaffirmed a "hold" rating and issued a $7.00 target price on shares of Sionna Therapeutics in a report on Monday. Wall Street Zen downgraded Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Raymond James Financial lowered Sionna Therapeutics from a "strong-buy" rating to a "market perform" rating in a research note on Monday. Finally, Freedom Capital cut Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $42.22.

Sionna Therapeutics Stock Performance

Shares of SION traded down $46.38 during mid-day trading on Monday, reaching $4.67. The company had a trading volume of 34,579,355 shares, compared to its average volume of 623,337. The company has a market capitalization of $210.90 million, a price-to-earnings ratio of -2.14 and a beta of 1.32. The company's 50 day simple moving average is $42.35 and its 200 day simple moving average is $40.42. Sionna Therapeutics has a 1-year low of $4.01 and a 1-year high of $54.97.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.02). As a group, equities analysts forecast that Sionna Therapeutics will post -2.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Orbimed Advisors Llc sold 115,844 shares of the company's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director directly owned 2,555,877 shares of the company's stock, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 115,844 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director owned 2,555,877 shares of the company's stock, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 403,726 shares of company stock worth $18,259,354 in the last 90 days. Corporate insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $35,000. GF Fund Management CO. LTD. bought a new position in Sionna Therapeutics during the fourth quarter worth $36,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Sionna Therapeutics in the second quarter worth $44,000. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics in the third quarter worth $30,000. Finally, Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics in the fourth quarter valued at $58,000.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Neutral Sentiment: Several analysts maintained cautious ratings while setting targets above the recent share price. Stifel Nicolaus reaffirmed a “hold” rating with a $7 target, while Wedbush reiterated “neutral” with a $5 target. Royal Bank of Canada upgraded Sionna from “underperform” to “sector perform,” also assigning a $5 target. The Fly analyst ratings
• Neutral Sentiment: Guggenheim reaffirmed its “neutral” rating, indicating that the firm does not currently see a clear catalyst to change its view. The Fly Guggenheim rating
• Negative Sentiment: Raymond James downgraded Sionna from “strong buy” to “market perform,” and Citizens JMP cut its rating from “market outperform” to “market perform.” The downgrades reflect reduced confidence following the clinical update. The Fly analyst downgrades
• Negative Sentiment: Sionna reported topline results from two cystic fibrosis development programs. Its experimental SION-719 therapy reportedly failed to demonstrate sufficiently encouraging results in a mid-stage trial, prompting the company to discontinue the program. The setback removes a key pipeline opportunity and is the primary reason investors are selling the stock. STAT Sionna cystic fibrosis trial report
• Negative Sentiment: The company is refocusing its cystic fibrosis pipeline after the trial setback, increasing uncertainty around its remaining development programs and potential future revenue. TipRanks Sionna trial update
• Negative Sentiment: Johnson Fistel announced an investigation into potential federal securities-law violations related to the sharp market reaction and the company’s disclosures. Although the investigation does not establish wrongdoing, it adds legal and reputational risk. Johnson Fistel investigation announcement

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source